Research programme: Chagas disease vaccines - Aeras/Baylor College of Medicine/Eisai/Sabin Vaccine Institute

Drug Profile

Research programme: Chagas disease vaccines - Aeras/Baylor College of Medicine/Eisai/Sabin Vaccine Institute

Latest Information Update: 30 Jul 2015

Price : $50

At a glance

  • Originator Sabin Vaccine Institute
  • Developer Aeras; Baylor College of Medicine; Eisai Co Ltd; Sabin Vaccine Institute
  • Class Recombinant proteins; Vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease

Most Recent Events

  • 28 Jul 2015 The Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development receive a grant from The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation for vaccine development for Chagas disease
  • 15 Sep 2014 Early research in Chagas' disease in USA (Parenteral)
  • 15 Sep 2014 Sabin vaccine Institute, Eisai, Aeras, Baylor College of Medicine receive a grant from Global Health Innovative Technology Fund for vaccine development in Chagas disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top